U.S., Sept. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07179926) titled 'Effects of Pasireotide Lar Therapy on Bone Metabolism' on June 24.
Brief Summary: Acromegaly, a chronic condition characterized by growth hormone (GH) and, in turn, insulin-like growth factor-1 (IGF-I) excess, is burdened by a series of systemic and metabolic comorbidities that strongly impair quality of life (QoL) and life expectancy. Amongst them, a specific acromegalic osteopathy has been discovered, characterized by fragility fractures associated with high bone turnover, which need to be early detected, according to most recent guidelines, since they are very frequent and related to chronic pain and reduced QoL. Morphometric ve...